Moderna’s updated COVID-19 vaccine for Autumn 2023 outperforms in cost and clinical impact

Moderna’s updated mRNA-1273.815 COVID-19 vaccine shows promising results in reducing symptomatic cases, hospitalizations, and deaths in high-risk and older adults in Germany. The study finds the vaccine to be more cost-effective and clinically beneficial than both no vaccination and Pfizer’s XBB.1.5 BNT162b2 vaccine.